Davita Inc vs iShares International Treasury Bond ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B). The key difference: Davita Inc is far larger — about 8.7× iShares International Treasury Bond ETF's market cap, and Davita Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares International Treasury Bond ETF for 92 Days on average.
| DVA | IGOV | |
|---|---|---|
Market Cap | $11.29B | $1.30B |
Volume | 582,204 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $42.99 |
52-Week Low | $103.87 | $39.65 |
Typical Hold Time | 113 Days | 92 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
IGOV trades at $39.70, down 0.48% with a bearish technical outlook as moving averages signal selling pressure. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental assessment. Recent news highlights rising global bond yields, which may impact interest-rate sensitive sectors. The stock shows neutral oscillator signals with RSI levels near oversold territory at 30-37.
Investment outlook remains cautious due to incomplete financial data and bearish technical indicators. Rising Treasury yields pose macroeconomic headwinds, while the absence of valuation metrics complicates risk-reward analysis. Investors require updated SEC filings and earnings reports to properly evaluate the company's financial health and growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →